Immunological Effects of BRAF+MEK Inhibition

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2018 Sep 20

PMID 30228935

Citations 40

Authors

Paolo A Ascierto

Reinhard Dummer

Affiliations

Soon will be listed here.

Abstract

Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, without brain metastases, and low tumor burden. This long-term benefit of targeted therapies might be related to an immune-modulation: indeed BRAF and MEK inhibitors affect tumor microenvironment and immune surveillance, and it has been shown that patients with complete response to targeted treatment have a pre-existing favorable immunologic signature.

Citing Articles

Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status.

Placke J, Rajcsanyi L, Herbst R, Terheyden P, Utikal J, Pfohler C Front Immunol. 2025; 16:1536642.

PMID: 40028330 PMC: 11868123. DOI: 10.3389/fimmu.2025.1536642.

Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF-mutant advanced melanoma: a multicenter cohort study.

Wu J, Ding Q, Zhang Q, Chen Q, Wen X, Ding Y MedComm (2020). 2025; 6(3):e70102.

PMID: 39968494 PMC: 11832434. DOI: 10.1002/mco2.70102.

The tumour microenvironment of pilocytic astrocytoma evolves over time via enrichment for microglia.

Stone T, Pickles J, Ogunbiyi O, Yasin S, Taylor C, Ahmed S Acta Neuropathol Commun. 2025; 13(1):30.

PMID: 39948623 PMC: 11823165. DOI: 10.1186/s40478-024-01922-9.

Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma-A Systematic Review and Network Meta-Analysis.

Lengyel A, Meznerics F, Galajda N, Gede N, Koi T, Mohammed A Int J Mol Sci. 2024; 25(23).

PMID: 39684531 PMC: 11641726. DOI: 10.3390/ijms252312821.

Innate Immune Cells in Melanoma: Implications for Immunotherapy.

Trocchia M, Ventrici A, Modestino L, Cristinziano L, Ferrara A, Palestra F Int J Mol Sci. 2024; 25(15).

PMID: 39126091 PMC: 11313504. DOI: 10.3390/ijms25158523.

References

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

Carlino M, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L . Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer. 2016; 115(11):1280-1284. PMC: 5129828. DOI: 10.1038/bjc.2016.321. View

Schadendorf D, Wolchok J, Hodi F, Chiarion-Sileni V, Gonzalez R, Rutkowski P . Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017; 35(34):3807-3814. PMC: 5791828. DOI: 10.1200/JCO.2017.73.2289. View

Boshuizen J, Koopman L, Krijgsman O, Shahrabi A, van den Heuvel E, Ligtenberg M . Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018; 24(2):203-212. DOI: 10.1038/nm.4472. View

Ascierto P, Simeone E, Giannarelli D, Grimaldi A, Romano A, Mozzillo N . Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012; 10:107. PMC: 3464706. DOI: 10.1186/1479-5876-10-107. View

Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C . Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14):1345-1356. PMC: 5706778. DOI: 10.1056/NEJMoa1709684. View

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603-615. DOI: 10.1016/S1470-2045(18)30142-6. View

Schilling B, Paschen A . Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells. Oncoimmunology. 2013; 2(8):e25218. PMC: 3805652. DOI: 10.4161/onci.25218. View

Ascierto P, Long G . Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol. 2016; 17(8):1037-1039. DOI: 10.1016/S1470-2045(16)30017-1. View

10.

da Silveira Nogueira Lima J, Georgieva M, Haaland B, de Lima Lopes G . A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Med. 2017; 6(6):1143-1153. PMC: 5463084. DOI: 10.1002/cam4.1001. View

11.

Frederick D, Piris A, Cogdill A, Cooper Z, Lezcano C, Ferrone C . BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5):1225-31. PMC: 3752683. DOI: 10.1158/1078-0432.CCR-12-1630. View

12.

Hu-Lieskovan S, Mok S, Moreno B, Tsoi J, Robert L, Goedert L . Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015; 7(279):279ra41. PMC: 4765379. DOI: 10.1126/scitranslmed.aaa4691. View

13.

Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long G . Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol. 2013; 31(12):e215-7. DOI: 10.1200/JCO.2012.45.7028. View

14.

Long G, Atkinson V, Ascierto P, Robert C, Hassel J, Rutkowski P . Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol. 2016; 27(10):1940-6. PMC: 5035785. DOI: 10.1093/annonc/mdw265. View

15.

Simeone E, Grimaldi A, Festino L, Giannarelli D, Vanella V, Palla M . Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. Oncoimmunology. 2017; 6(3):e1283462. PMC: 5384373. DOI: 10.1080/2162402X.2017.1283462. View

16.

Dummer R, Ramelyte E, Schindler S, Thurigen O, Levesque M, Koelblinger P . MEK inhibition and immune responses in advanced melanoma. Oncoimmunology. 2017; 6(8):e1335843. PMC: 5593717. DOI: 10.1080/2162402X.2017.1335843. View

17.

Shoushtari A, Munhoz R, Kuk D, Ott P, Johnson D, Tsai K . The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016; 122(21):3354-3362. PMC: 5134420. DOI: 10.1002/cncr.30259. View

18.

Wilmott J, Long G, Howle J, Haydu L, Sharma R, Thompson J . Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2011; 18(5):1386-94. DOI: 10.1158/1078-0432.CCR-11-2479. View

19.

Johnpulle R, Johnson D, Sosman J . Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr Oncol Rep. 2016; 18(1):6. PMC: 10203820. DOI: 10.1007/s11912-015-0485-6. View

20.

Ugurel S, Rohmel J, Ascierto P, Flaherty K, Grob J, Hauschild A . Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017; 83:247-257. DOI: 10.1016/j.ejca.2017.06.028. View